CLARIFY

Mark For: CLARIFY™ trademark registration is intended to cover the categories of rapid lateral flow assays; Real time Polymerase Chain Reaction Medical diagnostic tests; Real time Polymerase Chain Reaction lyophilized products for laboratories; Polymerase Chain Reaction assays; Lower nostril nasal swab for detection of infectious disease; Nasopharyngeal tests for detection of infectious disease; Medical diagnostic test for detection of nucleic acid from SARS-CoV-2; Diagnostic tests for detection of infectious diseases on surfaces; Medical diagnostic test strips, cassette, trays, and devices for infectious disease; Medical diagnostic test strips, cassette, trays, and devices for infectious disease for point of care, laboratory, and home use; Rapid medical diagnostic test strips, cassette, trays, and devices for infectious disease; Medical diagnostic tests for Influenza A, Influenza B, SARS, Covid-19, SARS-CoV-2, Coronavirus, and respiratory illnesses; Cell-based medical diagnostic tests for Influenza A, Influenza B, SARS, Covid-19, SARS-CoV-2, Coronavirus, and respiratory illnesses; Rapid medical diagnostic tests for Influenza A, Influenza B, Covid-19, SARS-CoV-2, Coronavirus, and respiratory illnesses; Medical diagnostic tests for Influenza A, Influenza B, SARS, Covid-19, SARS-CoV-2, Coronavirus, and respiratory illnesses for point of care, laboratory, and home use; Medical diagnostic antigen tests; Rapid medical diagnostic antigen tests; Medical diagnostic antigen tests for point of care, laboratory, and home use; Medical diagnostic tests for oncology; Rapid medical diagnostic tests for oncology; Medical diagnostic tests for oncology for point of care, laboratory, and home use; Medical diagnostic tests for cardiac markers; Medical diagnostic antibody tests; Rapid medical diagnostic antibody tests; Medical diagnostic antibody tests for point of care, laboratory, and home use; Medical diagnostic vitamin D tests; Rapid medical diagnostic vitamin D tests; Medical diagnostic vitamin D tests for point of care, laboratory, and home use; Medical diagnostic opioid tests; Rapid medical diagnostic opioid tests; Medical diagnostic opioid tests for point of care, laboratory, and home use; Testing kits comprised of medical devices and diagnostic reagents and assays for testing bodily fluids, blood, DNA, RNA, and skin; Testing kits comprised of medical devices and diagnostic reagents and assays for rapid testing bodily fluids, blood, DNA, RNA, and skin; Testing kits comprised of medical devices and diagnostic reagents and assays for testing bodily fluids, blood, DNA, RNA, and skin for point of care, laboratory, and home use; Medical diagnostic tumor tests; Rapid medical diagnostic tumor tests; Medical diagnostic tumor tests for point of care, laboratory, and home use; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease and virus detection; Diagnostic kits comprised of medical diagnostic reagents and assays for rapid testing of bodily fluids for use in disease and virus detection; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease and virus detection for point of care, laboratory, and home use; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease and virus detection for animals; Healthcare services; Reporting qualitative and quantitative medical diagnostic test results; Medical diagnostic testing, monitoring and reporting services; Medical testing for diagnostic or treatment purposes; Rapid, single-use molecular diagnostic test kit for the qualitative detection of SARS-CoV-2 RNA from self-collected nasal swab specimens; Rapid, single-use molecular diagnostic test kit for the qualitative detection of SARS-CoV-2 RNA with isothermal amplification (LAMP) and test results displayed via LED indicators; Rapid, single-use molecular diagnostic test kit for the qualitative detection of SARS-CoV-2 RNA with Positive Internal Control (PIC) and Lysis Internal Control (LIC) contained within the test unit; Syndromic infections disease tests; Syndromic infections disease tests for severe acute respiratory syndrome; Nucleic acid test for qualitative detection of respiratory viral and bacterial nucleic acids; In vitro immunochromatographic assay for the direct qualitative detection of Sars - Cov 2 viral nucleoprotein antigens from nasal and nasopharyngeal secretions; Analysis of nucleic acids and run temperature cycles enabling DNA and RNA detection using qPCR and isothermal amplifications; Antibody detection of anti-Sars-COV-2 IgM and anti Sars - COV-2 OgG in human blood, serum or plasma; Antigen test, namely, immunochromatographic assay for the detection of the viral nucleoprotein; RT-PCR (Reverse-transcription polymerase chain reaction) tests; Transcription-mediated amplification (TMA) tests; Interactive Skin test to measure T-Cell Immunity.

Status

2021-07-22 UTC
⟳ Refresh

LIVE APPLICATION Awaiting Examination

Research	OneLook Acronym Finder
Serial Number	90836111
Mark Literal Elements	CLARIFY
Mark Drawing Type	4 - STANDARD CHARACTER MARK
Mark Type	Trademark
Current Location	NEW APPLICATION PROCESSING 2021-07-22
Basis	1(b)
Class Status	ACTIVE
Primary US Classes	005: Adhesives 006: Chemicals and Chemical Compositions 018: Medicines and Pharmaceutical Preparations 044: Dental, Medical and Surgical Appliances 046: Foods and Ingredients of Foods 051: Cosmetics and Toilet Preparations 052: Detergents and Soaps
Primary International Class	005 - Primary Class (Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use	No
Current Use	No
Intent To Use	Yes
Filed ITU	Yes
44D Filed	No
44E Current	No
66A Current	No
Current Basis	No
No Basis	No
Attorney Name	Courtney Thompson

Timeline